Skip to main content
Top
Published in: The Patient - Patient-Centered Outcomes Research 6/2022

01-11-2022 | COVID-19 | Original Research Article

Development of an Item Bank to Assess Patient-Reported Outcomes: Signs, Symptoms, and Impacts of COVID-19

Authors: Matthew Reaney, James Turnbull, Jean Paty, Karli Heuer, Chad Gwaltney

Published in: The Patient - Patient-Centered Outcomes Research | Issue 6/2022

Login to get access

Abstract

Background and Objective

Patients experience a wide range of signs, symptoms, and impacts related to coronavirus disease 2019 (COVID-19). A patient-reported outcome (PRO) item bank that measures the most relevant patient experiences is needed to fully evaluate treatment benefit in COVID-19 clinical trials.

Methods

A review of the literature and social media informed a novel PRO item bank of COVID-19 signs, symptoms, and impacts and general pandemic impacts. Twenty 1:1 concept elicitation and cognitive debriefing interviews were conducted with adults in the US who had symptomatic COVID-19. A conceptual model was developed and the PRO item bank refined following interviews.

Results

A heterogenous set of signs, symptoms, and impacts of COVID-19, as well as impacts associated with the pandemic overall, was identified. Fifty-five short-term and long-term signs and symptom items, 26 items assessing disease-related impacts, and seven items evaluating pandemic-related impacts are included in the item bank.

Conclusions

The novel and preliminarily content-valid IQVIA COVID-19 Daily Diary Item Bank© and the IQVIA COVID-19 Weekly Diary Item Bank© were developed to measure signs and symptoms, their associated severity, and disease-related and pandemic-related impacts. The items are arranged in seven groups and can be individually selected based on research needs.
Appendix
Available only for authorised users
Literature
2.
go back to reference Tessitore E, Mach F. Impact of COVID-19 on quality of life. E-Journal Cardiol Pract. 2021;21(3). Tessitore E, Mach F. Impact of COVID-19 on quality of life. E-Journal Cardiol Pract. 2021;21(3).
3.
go back to reference Wiegele PN, et al. Symptom diary-based analysis of disease course among patients with mild coronavirus disease, Germany, 2020. Emerg Infect Dis. 2021;27(5):1353. CrossRef Wiegele PN, et al. Symptom diary-based analysis of disease course among patients with mild coronavirus disease, Germany, 2020. Emerg Infect Dis. 2021;27(5):1353. CrossRef
4.
go back to reference Bastiani L, et al. Rapid COVID-19 screening based on self-reported symptoms: psychometric assessment and validation of the EPICCOVID19 Short Diagnostic Scale. J Med Internet Res. 2021;23(1): e23897.CrossRef Bastiani L, et al. Rapid COVID-19 screening based on self-reported symptoms: psychometric assessment and validation of the EPICCOVID19 Short Diagnostic Scale. J Med Internet Res. 2021;23(1): e23897.CrossRef
5.
go back to reference Jeong H, et al. Self-assessment questionnaire for efficient and safe evaluation of patients with mild COVID-19. Infect Chemother. 2020;52(2):212.CrossRef Jeong H, et al. Self-assessment questionnaire for efficient and safe evaluation of patients with mild COVID-19. Infect Chemother. 2020;52(2):212.CrossRef
6.
go back to reference Klok, et al. The Post-COVID-19 Functional Status Scale: a tool to measure functional status over time after COVID-19. Eur Respir J. 2020;56(1):2001494. CrossRef Klok, et al. The Post-COVID-19 Functional Status Scale: a tool to measure functional status over time after COVID-19. Eur Respir J. 2020;56(1):2001494. CrossRef
10.
go back to reference Bhattacharya A, et al. Development and validation of a clinical symptom-based scoring system for diagnostic evaluation of COVID-19 patients presenting to outpatient department in a pandemic situation. Cureus. 2021;13(3): e13681.PubMedPubMedCentral Bhattacharya A, et al. Development and validation of a clinical symptom-based scoring system for diagnostic evaluation of COVID-19 patients presenting to outpatient department in a pandemic situation. Cureus. 2021;13(3): e13681.PubMedPubMedCentral
12.
go back to reference Huang C, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497–506.CrossRef Huang C, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497–506.CrossRef
13.
go back to reference Lai CC, Shih TP, Ko WC, Tang HJ, Hsueh PR. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): the epidemic and the challenges. Int J Antimicrob Agents. 2020;55(3): 105924.CrossRef Lai CC, Shih TP, Ko WC, Tang HJ, Hsueh PR. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): the epidemic and the challenges. Int J Antimicrob Agents. 2020;55(3): 105924.CrossRef
14.
go back to reference Xu XW, et al. Clinical findings in a group of patients infected with the 2019 novel coronavirus (SARS-Cov-2) outside of Wuhan, China: retrospective case series. BMJ. 2020;368: m606.CrossRef Xu XW, et al. Clinical findings in a group of patients infected with the 2019 novel coronavirus (SARS-Cov-2) outside of Wuhan, China: retrospective case series. BMJ. 2020;368: m606.CrossRef
15.
go back to reference Zhang JJ, et al. Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China. Allergy. 2020;75(7):1730–41.CrossRef Zhang JJ, et al. Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China. Allergy. 2020;75(7):1730–41.CrossRef
16.
go back to reference Casas CG, et al. Classification of the cutaneous manifestations of COVID-19: a rapid prospective nationwide consensus study in Spain with 375 cases. Br J Dermatol. 2020;183(1):71–7.CrossRef Casas CG, et al. Classification of the cutaneous manifestations of COVID-19: a rapid prospective nationwide consensus study in Spain with 375 cases. Br J Dermatol. 2020;183(1):71–7.CrossRef
17.
go back to reference Flynn KE, Dombeck CB, DeEitt EM, Schulman KA, Weinfurt KP. Using item banks to construct measures of patient reported outcomes in clinical trials: investigator perceptions. Clin Trials. 2008;5(6):575–86.CrossRef Flynn KE, Dombeck CB, DeEitt EM, Schulman KA, Weinfurt KP. Using item banks to construct measures of patient reported outcomes in clinical trials: investigator perceptions. Clin Trials. 2008;5(6):575–86.CrossRef
18.
go back to reference Qiu R, et al. Core outcome set for clinical trials of COVID-19 based on traditional Chinese and Western medicine. Front Pharmacol. 2020;11:781.CrossRef Qiu R, et al. Core outcome set for clinical trials of COVID-19 based on traditional Chinese and Western medicine. Front Pharmacol. 2020;11:781.CrossRef
20.
go back to reference Patrick DL, et al. Content validity–establishing and reporting the evidence in newly developed patient-reported outcomes (PRO) instruments for medical product evaluation: ISPOR PRO good research practices task force report: part 1–eliciting concepts for a new PRO instrument. Value Health. 2011;14(8):967–77.CrossRef Patrick DL, et al. Content validity–establishing and reporting the evidence in newly developed patient-reported outcomes (PRO) instruments for medical product evaluation: ISPOR PRO good research practices task force report: part 1–eliciting concepts for a new PRO instrument. Value Health. 2011;14(8):967–77.CrossRef
21.
go back to reference Patrick DL, et al. Content validity—establishing and reporting the evidence in newly developed patient-reported outcomes (PRO) instruments for medical product evaluation: ISPOR PRO Good Research Practices Task Force report: part 2–assessing respondent understanding. Value Health. 2011;14(8):978–88.CrossRef Patrick DL, et al. Content validity—establishing and reporting the evidence in newly developed patient-reported outcomes (PRO) instruments for medical product evaluation: ISPOR PRO Good Research Practices Task Force report: part 2–assessing respondent understanding. Value Health. 2011;14(8):978–88.CrossRef
22.
go back to reference Wright BD, Bell SR. Item banks: what, why, how. J Educ Measure. 1984;21(4):331–45.CrossRef Wright BD, Bell SR. Item banks: what, why, how. J Educ Measure. 1984;21(4):331–45.CrossRef
24.
go back to reference Turner-Bowker BD, et al. Informing a priori sample size estimation in qualitative concept elicitation interview studies for clinical outcome assessment instrument development. Value Health. 2018;21(7):839–42.CrossRef Turner-Bowker BD, et al. Informing a priori sample size estimation in qualitative concept elicitation interview studies for clinical outcome assessment instrument development. Value Health. 2018;21(7):839–42.CrossRef
Metadata
Title
Development of an Item Bank to Assess Patient-Reported Outcomes: Signs, Symptoms, and Impacts of COVID-19
Authors
Matthew Reaney
James Turnbull
Jean Paty
Karli Heuer
Chad Gwaltney
Publication date
01-11-2022
Publisher
Springer International Publishing
Keyword
COVID-19
Published in
The Patient - Patient-Centered Outcomes Research / Issue 6/2022
Print ISSN: 1178-1653
Electronic ISSN: 1178-1661
DOI
https://doi.org/10.1007/s40271-022-00591-x

Other articles of this Issue 6/2022

The Patient - Patient-Centered Outcomes Research 6/2022 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine